Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS. METHODS: In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an additional 10 weeks. The primary end point, the proportion of patients who had adequate relief of global IBS symptoms, and the key secondary end point, the proportion of patients who had adequate relief of IBS-related bloating, were assessed weekly. Adequate relief was defined as self-reported relief of symptoms for at least 2 of the first 4 weeks after treatment. Other secondary end points included the percentage of patients who had a response to treatment as assessed by daily self-ratings of global IBS symptoms and individual symptoms of bloating, abdominal pain, and stool consistency during the 4 weeks after treatment and during the entire 3 months of the study. RESULTS: Significantly more patients in the rifaximin group than in the placebo group had adequate relief of global IBS symptoms during the first 4 weeks after treatment (40.8% vs. 31.2%, P=0.01, in TARGET 1; 40.6% vs. 32.2%, P=0.03, in TARGET 2; 40.7% vs. 31.7%, P<0.001, in the two studies combined). Similarly, more patients in the rifaximin group than in the placebo group had adequate relief of bloating (39.5% vs. 28.7%, P=0.005, in TARGET 1; 41.0% vs. 31.9%, P=0.02, in TARGET 2; 40.2% vs. 30.3%, P<0.001, in the two studies combined). In addition, significantly more patients in the rifaximin group had a response to treatment as assessed by daily ratings of IBS symptoms, bloating, abdominal pain, and stool consistency. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools. (Funded by Salix Pharmaceuticals; ClinicalTrials.gov numbers, NCT00731679 and NCT00724126.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Placebo-controlled studies of antibiotic (rifaximin) treatment in FGIDs and IBS have demonstrated significant reduction in bloating scores with rifaximin compared to placebo150–152.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A short course of a non-absorbable antibiotic such as rifaximin has been shown to moderately improve the symptoms of irritable bowel syndrome (IBS), particularly bloating and flatulence.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, it is likely that patients may require repeated courses of therapy, as trial evidence suggests the benefit diminishes by 12 weeks.189”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The sample size calculation was based on a one-sided α level of 0·0125 to account for two primary end points, an assumed placebo response rate of 40 % and a treatment difference of 10 % in responder rates based on previously published studies( 23 , 28 ). Further, accounting for a potential 10 % dropout rate and three interim analyses, 580 subjects in each group were required, totalling to 1740 sub”
From Effect of the probiotic strain Bifidobacterium animalis subsp. lactis , BB-12 ® , on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial (2015) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, treatments that change the microbiota, such as antibiotics or fecal microbiota transplant, 19,20 may be bene fi cial in a subset of patients with IBS.”
From Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis (2023) · cites this paper as [19]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Self-citationPimentel, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05902-6 · Cited by 669
Self-citationSmall intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00004 · Cited by 466
Self-citationSharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344
Attar, A., Flourié, B., Rambaud, J., Franchisseur, C., Ruszniewski, P., & Bouhnik, Y. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70336-7 · Cited by 234
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Self-citation
Research works printed but not linked: 1
- El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health- related quality of life. Rev Gastroenterol Disord 2003;3:Suppl 2:S3-S11.
Cited by
Items 801–900 of 1,000
The Emerging Role of Microbiome–Gut–Brain Axis in Functional Gastrointestinal Disorders
Skonieczna‐Żydecka, K., Łoniewski, I., Koulaouzidis, A., & Marlicz, W. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815249-2.00026-9 · Cited by 1
Síndrome de intestino irritable: La importancia de los antiespasmódicos
Fernández, L. M. B. (2020) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.523 · Cited by 2
Abdominelle Distension und Blähungen
Misselwitz, B., & Wiest, R. (2021) · Schweizer Gastroenterologie · doi:10.1007/s43472-021-00048-w · Cited by 1
Small Intestinal Bacterial Overgrowth
Ghoshal, U. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00107-9 · Cited by 1
Microbioma y enfermedades crónicas
Khouri, L. S., Flores-Andrade, X. A., González, R. S. M., Olmos, I. O. V., Velez-Pintado, M., & Durán, J. P. G. (2022) · Anales Médicos de la Asociación Médica del Centro Médico ABC · doi:10.35366/108781 · Cited by 1
The Microbiome in Neurogastroenterology
Preidis, G. A., Chumpitazi, B. P., & Shulman, R. J. (2022) · Springer eBooks · doi:10.1007/978-3-031-15229-0_6 · Cited by 1
Faruqui, A. A. (2023) · Journal of Medical Sciences · doi:10.4103/jmedsci.jmedsci_163_23 · Cited by 1
IBS and Chronic Prostatitis: Update on Chronic Pelvic Pain
Eltahawy, E. A., Lelovic, N., Quallich, S. A., & Machado, B. (2024) · Current Bladder Dysfunction Reports · doi:10.1007/s11884-024-00740-y · Cited by 1
“Safety was further tested and no resistance was seen in the microbiome, and the development of C. difficile colitis was rare [55].”
Tomasiewicz, K., Woroń, J., Kobayashi, A., Krasiński, Z., Rydzewska, G. M., & Szymański, F. M. (2024) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16728 · Cited by 4
Balsiger, L. M., Santos, J., Serra, J., Piessevaux, H. H., Baert, D., Storr, M., Basilisco, G., Mazzetti, A., Moro, L., Gerloni, M., et al. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003236 · Cited by 1
Camilleri, M., & Ford, A. C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18527 · Cited by 1
“For example, when compared with placebo, rifaximin showed significant effects on global symptoms and bloating in patients with non-constipated IBS [37], but had no significant effect on stool frequency or consistency in IBS-D [6].”
Onofrijchuk, Y. A. (2025) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.21.2.2025.1502 · Cited by 1
The Potential of Algal Oil for Biodiesel Production: A Systematic Review
Abdulla, G. A., & Alismaeel, Z. T. (2025) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/1507/1/012046 · Cited by 4
“Additionally, algae can grow in a range of conditions, including fresh and salt water, and because they don't require a large amount of land, they are projected to be used commercially as energy crops [37].”
The Intestinal Microbiota and Intestinal Disease: Irritable Bowel Syndrome
Keren, N., & Gophna, U. (2011) · Springer eBooks · doi:10.1007/978-3-642-21680-0_15 · Cited by 1
“2006), even in patients who did not have SIBO at baseline (Pimentel et al. 2011; Dear et al. 2005).”
BackgroundIncorporating FODMAP Dietary Restrictions: Help or Hype?
Wolf, W. A., Kiraly, L. N., & Ireton-Jones, C. S. (2015) · Current Nutrition Reports · doi:10.1007/s13668-015-0131-9 · Cited by 2
Quigley, E. M. M. (2014) · Frontiers of gastrointestinal research · doi:10.1159/000356743 · Cited by 1
Non-Absorbed Antibiotic for Irritable Bowel Syndrome
Cash, B. D. (2011) · Current Gastroenterology Reports · doi:10.1007/s11894-011-0211-y · Cited by 1
“One of this issue’s Clinical Trials Reports considers a manuscript [1] describing the combined results of two large clinical trials aimed at identifying a possible effective therapy for a common condition, irritable bowel syndrome (IBS), and many of the symptoms that accompany IBS.”
BackgroundInfluentialPharmacotherapy for irritable bowel syndrome in the context of evidence-based medicine
Maev, I. V., Cheremushkin, S. V., Kucheryavyi, Y. A., & Черемушкина, Н. В. (2015) · Terapevticheskii arkhiv · doi:10.17116/terarkh20158724-10 · Cited by 1
Bucci, C., Santonicola, A., & Iovino, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802189-7.00040-x · Cited by 1
Martynov, V. L., & Khairdinov, A. K. (2015) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2015-3-49-62 · Cited by 1
Zhang, Y., Li, L., Guo, C., Mu, D., Feng, B., Zuo, X., & Li, Y. (2016) · Cited by 1
Syndrome de l’intestin irritable. Actualités concernant les mécanismes et la prise en charge
Sabaté, J. (2017) · Douleur et Analgésie · doi:10.1007/s11724-017-0533-4 · Cited by 1
Irritable bowel syndrome: How to improve decision making in clinical practice
Mearin, F., Rey, E., & Santander, C. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.11.004 · Cited by 1
Ткач, С. М., & Mirzabayeva, N. M. (2019) · Modern Gastroenterology · doi:10.30978/mg-2019-1-93 · Cited by 1
Mining Human Microbiome for Therapeutics
Ghattargi, V. C., Sape, K., Kumbhare, S. V., & Shouche, Y. S. (2019) · Springer eBooks · doi:10.1007/978-981-13-8315-1_18 · Cited by 2
Veränderungen der Darm-Gehirn-Achse beim Reizdarmsyndrom – Ein Update
Kühne, S. G., & Stengel, A. (2019) · Erfahrungsheilkunde · doi:10.1055/a-1008-7780 · Cited by 1
“[53] Pimentel M, Lembo A, Chey WD et al.”
BackgroundInfluentialMulticultural factors in the treatment of patients with functional gastrointestinal disorders
Sperber, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813037-7.00040-6 · Cited by 1
Diarrhea-Predominant Irritable Bowel Syndrome: Medical Management Update
Andrews, C. N., & Bradette, M. (2019) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwz034 · Cited by 4
“The most common AEs with rifaximin treatment included headache, upper respiratory tract infection and nausea (Table 4) (50,51).”
BackgroundMethodCojocariu, R. O., Ciobica, A. S., Balmuș, I.-M., Gorgan, L., Pădurariu, M., Stanciu, C., & Trifan, A. V. (2019) · E-Health and Bioengineering Conference (EHB) · doi:10.1109/ehb47216.2019.8969977 · Cited by 2
Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?
Zyryanov, S. K., & Александровна, Б. Е. (2020) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2020-65-7-8-52-62 · Cited by 1
“При дальнейшем наблюдении улучшение общих симптомов также оказалось сопоставимо в обоих исследованиях [66, 67].”
Kingsley, M. J., & Moshiree, B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813037-7.00030-3 · Cited by 2
Kamboj, A. K., Agarwal, S., Chedid, V. G., Iyer, P. G., Bailey, K. R., Harmsen, W. S., & Katzka, D. A. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001516 · Cited by 1
“N Engl J Med 2011;364:22–32 (3) Publication page viewswere 32,409 at 7 days and 49,759 at 30 days after publication (3).”
BackgroundProbióticos en Síndrome de Intestino Irritable: ¿Están listos para la práctica clínica?
Valdovinos-Díaz, M. A. (2021) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/mrrq4655 · Cited by 4
Different Pathophysiological Mechanisms of Irritable Bowel Syndrome
Ünal, M. (2022) · International Journal of Medical Science and Health Research · doi:10.51505/ijmshr.2022.6603 · Cited by 2
Pohl, D., Vavricka, S. R., Fox, M. R., Madisch, A., Studerus, D., Wiesel, P. H., Heinrich, H. S., Linas, I., Schoepfer, A. M., Schwizer, A., et al. (2023) · Praxis · doi:10.1024/1661-8157/a003988 · Cited by 2
From Discomfort to Delight: Diet's Impact on IBS-D
Islam, S. M. S. (2023) · Journal of Clinical Medical Research · doi:10.46889/jcmr.2023.4303
Psychological Factors and Treatments in Irritable Bowel Syndrome
Weinland, S. R., & Drossman, D. A. (2013) · Wiley eBooks · doi:10.1002/9781118444689.ch10 · Cited by 1
Antibiotics in irritable bowel syndrome: a novel approach to a challenging disorder
Quigley, E. M. M. (2011) · Clinical Investigation · doi:10.4155/cli.11.31 · Cited by 1
Functional Gastrointestinal Disorders and the Joint Hypermobility Syndrome
Fikree, A. (2013) · Cited by 1
Persistent Travelers' Diarrhea
Connor, B. A., & Shlim, D. R. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-1076-8.00021-1 · Cited by 2
Rifaximin in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
Dai, C., Jiang, M., & Sun, M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.068 · Cited by 2
Intestinal Microbiota, Alterations in Irritable Bowel Syndrome
Jeffery, I. B., Claesson, M. J., & O’Toole, P. W. (2015) · Springer eBooks · doi:10.1007/978-1-4899-7475-4_96 · Cited by 1
“This link to altered microbiota has led to the investigation of ways to manipulate the microbiota using minimally absorbed antibiotics (Pimentel et al. 2011), dietary fiber, and probiotics (Whelan 2011).”
BackgroundWeerts, Z. Z. R. M., Masclee, A., Jonkers, D. M. A. E., & Keszthelyi, D. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.04.010 · Cited by 1
Oh, C. J., & Rezaie, A. R. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07551-3 · Cited by 1
“Furthermore, rifaximin, a microbiome modulation drug which has improves all of the cardinal symptoms of IBS-D, has only minimal and transient effects on the stool microbiome composition [7], in contrast to the effects of rifaximin on the small bowel microbiome in the same phase III trial [3] (TARGET 3), in which IBS-D…”
BackgroundThe gut microbiome and gut-liver axis in NAFLDPreprint
Guo, C., Ji, J., Wu, J., Wu, L., Feng, J., Li, J., Yu, Q., Dai, W., Li, Y., & Zheng, Y. (2024) · Authorea · doi:10.22541/au.170666810.08665505/v1
Halmos, E. P., & Gibson, P. R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70452 · Cited by 1
“The response rate to rifaximin was in line with that previously reported in patients with non- constipation-predominant IBS [2].”
Irritable bowel syndrome pathogenesis
Farmer, A. D., & Aziz, Q. (2014) · Wiley eBooks · doi:10.1002/9781118872796.ch3.18
Gut Hypersensitivity Related Symptoms
Farmer, A. D., Peiris, M., & Aziz, Q. (2013) · Wiley eBooks · doi:10.1002/9781118444689.ch12
Irritable Bowel Syndrome and Microbial Pathogenesis
Fong, I. W. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1670-2_1
Diagnostic and Therapeutic Horizons for Irritable Bowel Syndrome
Tack, J. F. (2013) · Wiley eBooks · doi:10.1002/9781118444689.ch15
Ernährung beim Reizdarmsyndrom
Meier, R. F. (2011) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 3
Abdominal Bloating and Visible Distension
Hwang, L. J., & Pimentel, M. (2010) · Wiley eBooks · doi:10.1002/9781444328417.ch23
Self-citation1. Promising Pharmacological Therapy for FGID in the Future
Tominaga, K., Fujikawa, Y., Tanaka, F., Sogawa, M., Yamagami, H., Tanigawa, T., Shiba, M., Watanabe, K., Watanabe, T., Fujiwara, Y., et al. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.96
Use of Oral Antibiotics in Elderly Gastrointestinal Patients
Choe, S. C., M.D., PhD., P., & Lee, D. H. (2012) · Journal of the Korean Geriatrics Society · doi:10.4235/jkgs.2012.16.3.108
Microbiote et syndrome de l’intestin irritable (SII) : où en sommes-nous, où allons-nous ?
Duboc, H. (2013) · Côlon & Rectum · doi:10.1007/s11725-013-0459-5
VACCINATION STATUS IN CHILDREN UNDER 8 YEARS AND ATTITUDES OF THEIR PARENTS
Kut, A., & Geckil, A. (2014) · Turkish Journal of Family Medicine & Primary Care · doi:10.5455/tjfmpc.154621
Opluchting voor prikkelbare darmen?
Cals, J. (2011) · Huisarts en Wetenschap · doi:10.1007/s12445-011-0084-1
Rifaximin: Irritable Bowel Syndrome
Generali, J. A., & Cada, D. J. (2014) · Hospital Pharmacy · doi:10.1310/hpj4911-1014
Non-absorbed Antibiotics for IBS
Cash, B. D. (2012) · Journal of Developing Drugs · doi:10.4172/2329-6631.1000e111
“A recent manuscript [1] described two multi-center, prospective, double blind trials of the non-absorbed antibiotic rifaximin for nonconstipated irritable bowel syndrome (IBS).”
BackgroundTwo weeks of rifaximin relieves global symptoms and bloating in people with IBS without constipation
Spiegel, B. M. R. (2011) · BMJ Evidence-Based Medicine · doi:10.1136/ebm1404
Recent Publications on Medications and Pharmacy
Russett, F. (2012) · Hospital Pharmacy · doi:10.1310/hpj4705-401
¿Antimicrobianos para el síndrome de intestino irritable?
Frati-Munari, A. C. (2013) · Atención Familiar · doi:10.1016/s1405-8871(16)30108-0
Opinion: Refractory inflammatory bowel disease—could it be an irritable bowel?
Meng, J., Agrawal, A. K., & Whorwell, P. J. (2013)
Funktionelle Magen-Darm-Erkrankungen
Keller, J., & Layer, P. (2013) · Der Internist · doi:10.1007/s00108-013-3379-4
Inflammation, Microflora, Motility, and Visceral Sensitivity
Michail, S. K., & Ng, M.-W. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-709-9_5
Microbiote et intestin irritable
Duboc, H. (2014) · Côlon & Rectum · doi:10.1007/s11725-014-0539-1
Sotoudehmanesh, R., Akram, A., Khatibian, M., Movahedi, Z., & Heidari, Z. (2011) · GOVARESH
Protocolo diagnóstico del meteorismo abdominal
Tomé, A. P., & González, J. A. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.02.014
Álvarez-Sánchez, Á., Rey, E., Zakko, S. F., Yu, J., & Sm, M. (2013)
Self-citationReizdarmsyndrom - Diagnostik und Therapie
Keller, J. (2013)
Assessment of Consensus-Based Pharmacological Therapies in Irritable Bowel Syndrome
Abtahi, S. R., & Zareian, P. (2015) · Journal of Archives in Military Medicine · doi:10.5812/jamm.30057
Challenging the Existence of IBS-D
Habba, S. F. (2014) · Internal Medicine Open Access · doi:10.4172/2165-8048.s1-e001
“In continuing this saga and in a desperate move, clinicians have been searching for fundamental understanding of IBS-D where antibiotics and anti-inflammatory agents are entertained with questionable result at best [14].”
BackgroundReizdarmsyndrom – Diagnostik und Therapie
Pohl, D., Heinrich, H. S., & Misselwitz, B. (2014) · coloproctology · doi:10.1007/s00053-014-0438-9
Functional bowel disorders and the role of mind-body therapies—The ‘Editors Choice’
Brindley, J. H., & Robinson, N. (2013) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2013.05.002
Are Antibiotics Effective for IBS?
Lomangino, K. (2012) · Clinical Nutrition INSIGHT · doi:10.1097/01.nmd.0000415505.67671.09
Arai, M., Matsuoka, K., & Kanai∥, T. (2015) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.104.35 · Cited by 1
Funktionelle Magen-Darm-Erkrankungen: Was tun, wenn der Bauch streikt?
Keller, J., & Layer, P. (2014) · CME · doi:10.1007/s11298-014-1199-x
Pallentino, J. (2012) · The Internet Journal of Advanced Nursing Practice · doi:10.5580/2b9d
“An evolving approach to managing IBS-D is to manipulate the gut flora with probiotics and antibiotics, a strategy based on the idea that altered intestinal bacteria contribute to the development of IBS symptoms.(20,23)Indeed, promising results have been achieved with certain probiotics(2) and with the minimally absorb…”
BackgroundIrritable bowel syndrome: etiology, pathogenesis and pathophysiology
Almansa, C., & Houghton, L. A. (2013) · doi:10.2217/ebo.13.545
Dietary Interventions and Irritable Bowel Syndrome
Thomas, A., & Quigley, E. M. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802304-4.00020-7 · Cited by 1
Novoa-Farías, O., Frati-Munari, A. C., Flores-Juárez, S., Novoa-García, O., & Galicia-Tapia, J. (2016)
Irritable bowel syndrome: the next-to-last that is being investigated
Domingo, J. J. S. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.05.004 · Cited by 1
Sweetser, S. R., & Locke, G. R. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199373338.003.0023
Persistent Diarrhea in the Returned Traveler
Wright, S. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-4390-4.00146-6
Bacterial Overgrowth of the Small Intestine Breath Test
James, M. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-2333-5.00010-9
Guilarte, M. (2014) · TDX (Tesis Doctorals en Xarxa)
Yazdani, M., Aramesh, A., Rafiei, R., Daghaghzadeh, H., & Adibi, P. (2016) · Advanced Biomedical Research · doi:10.4103/2277-9175.192737
“Recent studies suggest the importance of bacteria and gut flora in the pathophysiology of IBS.[8,16,17] These studies linked IBS to small intestinal bacterial overgrowth (SIBO).”
BackgroundMethodResultInfluentialAutoimmunity and Irritable Bowel Syndrome: New Pathophysiology
Pimentel, M., Barlow, G. M., Kim, J. H., & Chang, C. C.-C. (2016) · The American Journal of Gastroenterology Supplements · doi:10.1038/ajgsup.2016.13
Self-citationCrijevna mikrobiota u pacijenata s poremećajima probavnog trakta
Fakultet, M. (2015)
Gastrointestinal Diseases During Pregnancy
Akbari, M., & Wolf, J. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-39328-5_1
Schmerztherapie beim Reizdarmsyndrom
Krankenhaus, I. (2014)
The dawn of the small bowel expert cometh!
Sanders, D. S. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000353
“[12] studies have shown short-term improvement of symptoms using rifaximin.”
BackgroundUse of probiotics in irritable bowel syndrome
Quigley, E. M. M. (2014) · doi:10.2217/ebo.13.517
Neue Optionen gegen Reizdarm in Sicht
Wettstein, M. (2017) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-017-9582-9
DIETARY TRIMETHYLAMINES, THE GUT MICROBIOTA,AND ATHEROSCLEROSIS
Koeth, R. (2013) · OhioLink ETD Center (Ohio Library and Information Network)
Metadata
- Authors
- Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Michigan Medicine (US)
- Bristol Hospital (US)
- University of North Carolina at Chapel Hill (US)
- Salix Pharmaceuticals (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-06
- Volume
- 364
- Issue
- 1
- Pages
- 22-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149216059
- Cited by
- 1,036
- References
- 21
- Citations by year
- 2026: 51 · 2025: 46 · 2024: 36 · 2023: 56 · 2022: 51 · 2021: 65 · 2020: 56 · 2019: 51 · 2018: 65 · 2017: 74 · 2016: 87 · 2015: 70 · 2014: 95 · 2013: 73 · 2012: 87
- FWCI
- 106.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- rifaximin, gut microbiota, bloating, abdominal pain, stool consistency, symptom relief, antibiotic therapy, IBS pathophysiology, TARGET trial, adverse events
- MeSH terms
- Rifaximin, Aged, Anti-Bacterial Agents, Diarrhea, Double-Blind Method, Female, Humans, Male, Middle Aged, Rifamycins, Abdominal Pain, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.